Biotech

All Articles

A better look at Fierce Biotech's Intense 15

.In this particular full week's incident of "The Best Line," our company're diving into Fierce Biote...

Lilly encounters phase 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's celebration celebrating the commendation of ...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings...

Lykos are going to ask FDA to reconsider its selection observing turndown of MDMA therapy for post-traumatic stress disorder

.Following a poor revealing for Lykos Therapeutics' MDMA applicant for post-traumatic stress disorde...

AN 2 fifty percents roll call, quits phase 3 trial after data let down

.AN2 Rehabs is rethinking its service in action to dull midphase records, swearing to lay off half i...

Merck pays for $700M for bispecific, spying autoimmune opening and opportunity to challenge Amgen in cancer

.Merck &amp Co. is spending $700 thousand upfront to challenge Amgen in a blood stream cancer cells ...

Gilead pays J&ampJ $320M to leave licensing package for seladelpar

.Along With Gilead Sciences almost an FDA decision for its own liver health condition medicine selad...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks can observe the firms establishing outdoors tents at basecamp r...

Entero laying off personnel, leaving office and pausing R&ampD

.Mattress Liquidators has turned Entero Therapies white colored as a slab. The lender ordered Entero...

Exelixis goes down ADC after deciding it's no match for Tivdak

.Exelixis is giving up on its own cells variable (TF)- targeting antibody-drug conjugate after wrapp...